VERACYTE, INC. (NASDAQ:VCYT) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On August 14, 2017, we entered into a Second Amendment to Lease Agreement (the “Amendment”) with BRI 1868 RIATA, LLC, which amends that certain Lease Agreement dated as of November 28, 2012 (as amended by that certain First Amendment to Lease Agreement dated January 7, 2014, collectively the “Lease”), for our laboratory and office facilities in Austin, Texas, covering approximately 10,364 rentable square feet of space.

The Lease term would have expired on July 31, 2018, and the Amendment extends the lease term until January 31, 2029. We have the option to extend the lease term for an additional five years. We also have the option to terminate the lease effective July 31, 2025. Base rentpayments under the Amendment are expected to be approximately $2.9 million in the aggregate over the term of the Amendment. We also are responsible for certain other costs under the Amendment, such as operating expenses, taxes and utilities.

The foregoing summary of key terms of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the Amendment, a copy of which the Company expects to file with the Company's Quarterly Report on Form 10-Q for the quarterly period ending September 30, 2017.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under item 1.01 of this report is incorporated herein by reference.

About VERACYTE, INC. (NASDAQ:VCYT)

Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.